Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

Oncotarget

Volumn 6, Issue 20, 2015, Pages 17895-17910

  Ghosh, Arindam P ^a   Marshall, Christopher B ^d   Coric, Tatjana ^b   Shim, Eun Hee ^a   Kirkman, Richard ^a   Ballestas, Mary E ^c   Ikura, Mitsuhiko ^d   Bjornsti, Mary Ann ^b   Sudarshan, Sunil ^a  

^a Hugh Kaul Human Genetics Building   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

mTOR; Mutations; Rapamycin; Renal cancer; RHEB

Indexed keywords

BINDING PROTEIN; DEP DOMAIN CONTAINING MTOR INTERACTING PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROLINE RICH AKT SUBSTRATE 40; RAPAMYCIN; RHEB PROTEIN; TUBERIN; UNCLASSIFIED DRUG; AKT1S1 PROTEIN, HUMAN; DEPTOR PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MTOR PROTEIN, HUMAN; MTOR PROTEIN, RAT; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; PROTEIN KINASE INHIBITOR; RHEB PROTEIN, HUMAN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE ACTIVATION; GENE CLUSTER; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MISSENSE MUTATION; MTOR GENE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; POINT MUTATION; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHEB GENE; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PHENOTYPE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GTPASE-ACTIVATING PROTEINS; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MONOMERIC GTP-BINDING PROTEINS; MULTIPROTEIN COMPLEXES; NEUROPEPTIDES; PHENOTYPE; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84938570135     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4963     Document Type: Article

References (61)

1. Laplante M and Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. Journal of cell science. 2013; 126:1713-1719.
2. Menon S and Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008; 27 Suppl 2:S43-51.
3. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499:43-49.
4. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45:860-867.
5. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature reviews Molecular cell biology. 2011; 12:21-35.
6. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002; 110:177-189.
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology : CB. 2004; 14:1296-1302.
8. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA and Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. The Biochemical journal. 2007; 405:513-522.
9. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA and Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular cell. 2007; 25:903-915.
10. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006; 127:125-137.
11. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P and Sabatini DM. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Molecular cell. 2003; 11:895-904.
12. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009; 137:873-886.
13. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB and Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995; 377:441-446.
14. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I and Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997; 272:26457-26463.
15. Kim SG, Buel GR and Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells. 2013; 35:463-473.
16. Tee AR, Manning BD, Roux PP, Cantley LC and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Current biology : CB. 2003; 13:1259-1268.
17. Inoki K, Li Y, Xu T and Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & development. 2003; 17:1829-1834.
18. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307:1098-1101.
19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-404.
20. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1.
21. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43:D805-811.
22. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ and Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497:217-223.
23. Sato T, Nakashima A, Guo L, Coffman K and Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010; 29:2746-2752.
24. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH and Sabatini DM. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer discovery. 2014; 4:554-563.
25. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB and Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science. 2013; 341:1236566.
26. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH and Sabatini DM. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014; 4:554-563.
27. Feng J, Park J, Cron P, Hess D and Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004; 279:41189-41196.
28. Huang J and Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37:217-222.
29. Alessi DR, Pearce LR and Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal. 2009; 2:pe27.
30. Dibble CC and Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013; 15:555-564.
31. Gingras AC, Raught B and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15:807-826.
32. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G and Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010; 328:1172-1176.
33. Wang L, Harris TE, Roth RA and Lawrence JC, Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. The Journal of biological chemistry. 2007; 282:20036-20044.
34. Aimbetov R, Chen CH, Bulgakova O, Abetov D, Bissenbaev AK, Bersimbaev RI and Sarbassov DD. Integrity of mTORC2 is dependent on the rictor Gly-934 site. Oncogene. 2012; 31:2115-2120.
35. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther. 2012; 13:1349-1354.
36. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England journal of medicine. 2014; 371:1426-1433.
37. Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, Stein U, Montange D, Foubert A, Nerich V, Pivot X and Royer B. Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014; 73:999-991007.
38. Manning BD, Tee AR, Logsdon MN, Blenis J and Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002; 10:151-162.
39. Inoki K, Li Y, Zhu T, Wu J and Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature cell biology. 2002; 4:648-657.
40. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L and Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008; 320:1496-1501.
41. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-404.
42. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES and Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495-501.
43. Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA and Chen J. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A. 2008; 105:8286-8291.
44. Avruch J, Long X, Lin Y, Ortiz-Vega S, Rapley J, Papageorgiou A, Oshiro N and Kikkawa U. Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem Soc Trans. 2009; 37:223-226.
45. Yu Y, Li S, Xu X, Li Y, Guan K, Arnold E and Ding J. Structural basis for the unique biological function of small GTPase RHEB. The Journal of biological chemistry. 2005; 280:17093-17100.
46. Wennerberg K, Rossman KL and Der CJ. The Ras superfamily at a glance. Journal of cell science. 2005; 118:843-846.
47. Mazhab-Jafari MT, Marshall CB, Ishiyama N, Ho J, Di Palma V, Stambolic V and Ikura M. An autoinhibited noncanonical mechanism of GTP hydrolysis by Rheb maintains mTORC1 homeostasis. Structure (London, England :1993). 2012; 20:1528-1539.
48. Castro AF, Rebhun JF, Clark GJ and Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. The Journal of biological chemistry. 2003; 278:32493-32496.
49. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C and Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutation research. 2008; 659:284-292.
50. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012; 3:954-987.
51. Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Annals of medicine. 2014; 46:372-383.
52. Hopkins BD, Hodakoski C, Barrows D, Mense SM and Parsons RE. PTEN function: the long and the short of it. Trends in biochemical sciences. 2014; 39:183-190.
53. Hardie DG and Alessi DR. LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC biology. 2013; 11:36.
54. Seshacharyulu P, Pandey P, Datta K and Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer letters. 2013; 335:9-18.
55. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014; 371:1426-1433.
56. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006; 66:1500-1508.
57. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002; 110:163-175.
58. Chen CH and Sarbassov dos D. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. The Journal of biological chemistry. 2011; 286:40386-40394.
59. Shanmugasundaram K, Block K, Nayak BK, Livi CB, Venkatachalam MA and Sudarshan S. PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene. 2013; 32:2027-2036.
60. Marshall CB, Ho J, Buerger C, Plevin MJ, Li GY, Li Z, Ikura M and Stambolic V. Characterization of the intrinsic and TSC2-GAP-regulated GTPase activity of Rheb by real-time NMR. Sci Signal. 2009; 2:ra3.
61. Marshall CB, Meiri D, Smith MJ, Mazhab-Jafari MT, Gasmi-Seabrook GM, Rottapel R, Stambolic V and Ikura M. Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts. Methods. 2012; 57:473-485.